|Calculated MW||This protein is fused with 6×his tag at the C-terminus, and has a calculated MW of 28 kDa. The predicted N-terminus is Gly 18. DTT-reduced Protein migrates as 33-40 kDa in SDS-PAGE due to glycosylation.|
|Other Names||KLK13, KLKL4, KLK-13, Kallikrein-13|
|Results||Measured by its ability to cleave the fluorogenic peptide substrate Boc-VPR-AMC. The specific activity is > 150 pmoles / min / µg.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in 20 mM MES, 150 mM NaCl, pH 6.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikrein-13 (KLK13) is also known as Kallikrein-like protein 4 (KLK-L4), is a secreted protein, belongs to the peptidase S1 family and Kallikrein subfamily. KLK-13 contains one peptidase S1 domain. KLK13 is mainly expressed in prostate, breast, testis and salivary gland. KLK13 may be involved in the pathogenesis and / or progression of breast and ovary cancers, and is regarded as a novel cancer biomarker. In addition, KLK13 interacts and forms complexes with several serum protease inhibitors, such as alpha2-macroglobulin, and its expression is regulated by steroid hormones.
Yousef G.M.,et al.J. Biol. Chem. 275:11891-11898(2000).
Komatsu N.,et al.J. Invest. Dermatol. 121:542-549(2003).
Andres A.M.,et al.Genet. Epidemiol. 31:659-671(2007).
Grimwood J.,et al.Nature 428:529-535(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.